SEARCH:   Advanced

Blood, 1 April 2008, Vol. 111, No. 7, pp. 3893-3895. Prepublished online as a Blood First Edition Paper on January 30, 2008; DOI 10.1182/blood-2007-10-120329. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-10-120329v1 111/7/3893    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Zohren, F. Articles by Haas, R. PubMed PubMed Citation Articles by Zohren, F. Articles by Haas, R. Related Collections Transplantation Cell Adhesion and Motility Brief Reports Clinical Trials and Observations Hematopoiesis Related Articles in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Brief Report The monoclonal anti–VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans Fabian Zohren1, Diamandis Toutzaris2, Viola Klärner1, Hans-Peter Hartung2, Bernd Kieseier2, and Rainer Haas1 Departments of1 Haematology, Oncology and Clinical Immunology; and 2 Neurology, Heinrich Heine-University, Düsseldorf, Germany We investigated the role of adhesion molecule VLA-4 in CD34+ blood stem-cell mobilization. Therefore, we examined 20 patients with multiple sclerosis (MS) who were treated with the anti–VLA-4 antibody natalizumab. Treated patients had received a median number of 4 natalizumab infusions (range: 2-9 infusions). Blood samples were taken 4 weeks following the last infusion. With a median proportion of 7.6 CD34+ cells/µL (range: 2.2-30.4 cells/µL), these patients had a significantly higher (P = .003) amount of circulating CD34+ cells compared with 5 healthy volunteers (median: 1.4/µL; range: 0.6-2.4/µL) and 5 untreated MS patients (median: 1.0/µL; range: 0.5-1.7/µL) (P = .001). Serial measurements in 4 patients receiving their first natalizumab infusion showed a maximal significant increase in circulating CD34+ cells from 3.3/µL (range: 1.6-4.8/µL) to 10.4/µL (range: 7.5-12.04/µL) 72 hours following natalizumab infusion (P = .001), including pluripotent cells in colony-forming assays. This mobilizing ability of natalizumab might be useful for patients with poor response to granulocyte colony-stimulating factor (G-CSF)–based protocols. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Articles in Blood Online: About multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors Carine Vuaillat, Géraldine Androdias, Nathalie Davoust, and Serge Nataf Blood 2008 112: 208-209. [Full Text] [PDF] Response: Natalizumab-induced mobilization of CD34+ hematopoietic progenitor cells Fabian Zohren Blood 2008 112: 210. [Full Text] [PDF] This article has been cited by other articles: R. A. Linker and B. C. Kieseier Review: Innovative monoclonal antibody therapies in multiple sclerosis Therapeutic Advances in Neurological Disorders, July 1, 2008; 1(1): 33 - 42. [Abstract] [PDF] C. Vuaillat, G. Androdias, N. Davoust, and S. Nataf About multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors Blood, July 1, 2008; 112(1): 208 - 209. [Full Text] [PDF] H. Bonig, A. Wundes, and T. Papayannopoulou Response: More about multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors Blood, July 1, 2008; 112(1): 209 - 210. [Full Text] [PDF] F. Zohren Response: Natalizumab-induced mobilization of CD34+ hematopoietic progenitor cells Blood, July 1, 2008; 112(1): 210 - 210. [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020